Melbourne, May 13, 2026, 07:35 AEST
- CSL ended Tuesday at A$98.55, slipping another 2.18%. That followed Monday’s sharp 15.96% drop, with shares still hovering close to the A$93.64 low marked during the initial sell-off.
- The decision came after a 90-day review that slashed FY26 revenue and profit forecasts, while also highlighting roughly US$5 billion more in non-cash pre-tax impairments expected between FY26 and FY27.
- Bulls point to a plasma heavyweight trading at low multiples, calling demand solid. Bears focus on yet another guidance reset, lingering fallout from Vifor, and brokers slashing targets at speed.
CSL’s selloff isn’t just about the disappointing number. The latest figure points to something deeper—a sign that the previous CSL model was simply too generous.
CSL last changed hands at A$98.55, having swung between A$94.76 and A$100.00 during Tuesday’s session on 4.66 million shares. That came right after Monday’s punishing drop—shares plunged 15.96% to close at A$100.75, bottoming out earlier at A$93.64. Not long ago this was considered a perennial safe bet on the ASX. The 52-week peak, for reference, is still way up at A$275.79.
The chart’s latest shift comes after interim chief executive Gordon Naylor wrapped up a 90-day review, putting FY26 revenue at about US$15.2 billion and NPATA at roughly US$3.1 billion on a constant currency basis. In other words, the company’s numbers exclude exchange-rate swings. NPATA—CSL’s go-to profit metric—backs out amortisation from acquired IP, plus major one-offs like restructuring or impairment costs.
The balance sheet is where the trouble really shows up. CSL flagged roughly US$5 billion in additional non-cash pre-tax impairments across FY26 and FY27, stacking on top of those already recorded at the half-year mark. An impairment, of course, means writing down asset values for accounting purposes—no cash leaves the business, but it signals the company’s earlier assumptions about those assets’ earnings won’t pan out. Here, CSL points to CSL Vifor intangibles, its product portfolio, and idle plant and equipment as the main sources of strain.
No ambiguity in the downgrade. CSL pointed to a US$300 million hit tied to U.S. immunoglobulin channel inventory, flagged another US$200 million on weaker China albumin values, and cited a US$150 million drag from Middle East conflict, slower HEMGENIX growth, and tougher iron competition. Immunoglobulin, a plasma-based antibody treatment for immune disorders, remains a core profit driver for the group.
Naylor looked to put the controversy behind him, but there was no attempt to gloss things over. He maintained CSL’s “growth initiatives are working,” though investors shouldn’t expect quick rewards—returns will take more time. During the investor call, he faced questions about CSL’s cost advantage head-on: “Yes, is the short answer,” he said when asked if it had slipped. Margins, he added, are “pretty robust” but, in his words, “not as good as we’d like.”
That’s significant—investors were told to be patient. The review followed Paul McKenzie’s unexpected departure and CSL’s February report of an 81% first-half profit slump. According to ABC, shares have fallen about 41% for 2026, and over the past year, losses top 57% after Monday’s steep drop. This isn’t just a single downgrade anymore.
The bullish argument hasn’t vanished, though it’s looking slimmer. CSL sees mid- to high-single digit growth in U.S. immunoglobulin demand, with its review highlighting persistent unmet needs in plasma therapies over the long haul. Bulls note the non-cash writedown leaves CSL’s core cash engine running. ETF Shares chief Cliff Man flagged the price-earnings ratio near 14, labeling the stock “very cheap” based on CSL’s standing in the sector.
The bear camp doesn’t hesitate: when trust collapses, “cheap” can always slide lower. Citi’s Laura Sutcliffe slashed her target to A$110, nearly halving it. Macquarie’s Christine Trinh also lowered her target, now at A$111, calling the saga a “bloody mess.” Bell Potter dropped its target to A$100. Canaccord revised its rating down to hold. Richard Coppleson, the Bell Potter stalwart, put it bluntly: there’s “never just one cockroach in the cupboard.” Sharecafe
CSL’s got a competitive headache here. According to Renta 4’s analysis, cited by The Corner, Grifols continues to see robust immunoglobulin demand—making CSL’s recent warning look less like a sector-wide issue and more like CSL’s own internal snag. That’s the blunt concern for shareholders: Grifols flags healthy demand, but CSL is bogged down talking inventory, pricing, and slow-moving internal gains.
Local healthcare stocks took a hit, with CSL at the epicenter. According to IG, the ASX 200 healthcare sector hovered around territory not visited since August 2017. ResMed dropped 3.63%, Pro Medicus slid 3.31% during Tuesday’s session. Neither company competes directly in plasma, but CSL’s move was enough to drag the whole sector back into the earnings-risk conversation.
The real evidence lands with CSL’s full-year results on August 18—details on financials and operations will have to wait. Between now and then, investors will be tracking U.S. immunoglobulin inventory to see if it finally moves, keeping an eye on whether albumin pricing in China finds its footing, looking for signs Vifor can stem its value bleed, and watching if the CEO hunt delivers a heavyweight able to overhaul capital allocation.
CSL isn’t behaving like your typical healthcare drop—it’s acting like a once high-flying stock searching for a comfortable valuation. Assets are still front and center, plasma remains a core story. Yet this week, investors are zeroing in: was CSL’s past success all about solid fundamentals, or was faith doing more of the heavy lifting?
